新靶点抗肿瘤药物研究进展

被引：11

作者：

陆鹏 ^{[1
]}

李增 ^{[2
]}

机构：

[1] 扬子江药业集团有限公司

[2] 中山大学药学院

来源：

现代医药卫生 | 2010年 / 26卷 / 05期

关键词：

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100706 [药理学];

摘要：

<正>近年来,随着肿瘤分子生物学及相关学科的飞速发展,人们逐渐认识到细胞癌变的本质可能是细胞信号转导通路的失调导致的细胞无限增殖,抗肿瘤药物研发理念发生了重大转变,从传统细胞毒类药物(主要作用于DNA,RNA和微管蛋白)转移到针对细胞内信号转导通路的新型抗肿瘤药物[1]。与传统

引用

页码：732 / 734

页数：3

共 11 条

[1]

Sunitinib: A VEGF and PDGF receptor protein kinase and angiogenesis inhibitor [J].

Roskoski, Robert, Jr. .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 356 (02) :323-328

[2]

Upregulated expression of PDGF receptor beta in endocrine pancreatic tumors and metastases compared to normal endocrine pancreas [J].

Fjallskog, Marie-Louise ;

Hessman, Ola ;

Eriksson, Barbro ;

Janson, Eva Tiensuu .

ACTA ONCOLOGICA, 2007, 46 (06) :741-746

[3]

Multitargeted therapy: Can promiscuity be praised in an era of political correctness? [J].

Jimeno, Antonio ;

Hidalgo, Manuel .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 59 (02) :150-158

[4]

Histone deacetylase inhibitors: Multifunctional anticancer agents [J].

Liu, Tao ;

Kuljaca, Selena ;

Tee, Andrew ;

Marshall, Glenn M. .

CANCER TREATMENT REVIEWS, 2006, 32 (03) :157-165

[5]

Antiangiogenesis in cancer therapy - endostatin and its mechanisms of action [J].

Folkman, J .

EXPERIMENTAL CELL RESEARCH, 2006, 312 (05) :594-607

[6]

Drug development in oncology: classical cytotoxics and molecularly targeted agents [J].

Kummar, Shivaani ;

Gutierrez, Martin ;

Doroshow, James H. ;

Murgo, Anthony J. .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (01) :15-26

[7]

Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours [J].

Mross, K ;

Drevs, J ;

Müller, M ;

Medinger, M ;

Marmé, D ;

Hennig, M ;

Morgan, B ;

Lebwohl, D ;

Masson, E ;

Ho, YY ;

Günther, C ;

Laurent, D ;

Unger, C .

EUROPEAN JOURNAL OF CANCER, 2005, 41 (09) :1291-1299

[8]

Back to the future with ubiquitin [J].

Pickart, CM .

CELL, 2004, 116 (02) :181-190

[9]

Tyrosine kinases as targets in cancer therapy – successes and failures.[J].Traxler.Expert Opinion on Therapeutic Targets.2003, 2

[10]

NOBEL LECTURE: Cyclin Dependent Kinases and Cell Cycle Control.[J].Paul M. Nurse.Bioscience Reports.2002, 5

← 1 2 →